ArticleDiscover oncology2025
Regulation of iodide transportation by a plant secondary metabolite in SW1736 anaplastic thyroid cancer cell line.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS AND
backgroundOwing to impaired iodine metabolism, anaplastic thyroid carcinoma, recognized as one of the most formidable malignancies, is resistant to radioiodine therapy. This study was conducted to determine the possible role of Genistein as plant secondary metabolite in understanding the effectiveness of this nutraceutical compound in modulating Sodium iodide symporter (NIS) expression and iodide uptake in the SW1736 anaplastic thyroid cancer cell linen. MATERIAL
methodsCell viability was assessed using the MTT assay, whereas cell apoptosis was assessed using a flow cytometry assay (Annexin V-FITC Apoptosis Detection kit). To determine iodide uptake by SW1736 cells, a Sandell-Kolthoff reaction-based spectrophotometric assay was performed. QRT-PCR and western blotting were used to measure NIS mRNA and protein levels in SW1736 cells.
resultsSW1736 cells exhibited time- and dose-dependent growth inhibition in response to Genistein treatment. QRT-PCR analysis revealed that NIS mRNA levels in the Genistein-treated group were significantly (p < 0.05) higher than those in the non-treated group. Accordingly, Western blot analysis revealed that SW1736 cells treated with Genistein expressed a high level of the NIS protein (p < 0.01). Compared with the control group, Genistein increased iodide uptake (p < 0.001) in the thyroid cancer cell line SW1736.
conclusionThe expression of NIS and subsequent iodine uptake after Genistein treatment suggest that ATC cells may be becoming more like differentiated thyroid cells, which typically have higher iodine uptake capabilities. However, this redifferentiation does not directly correlate with an increase in sensitivity to radioactive iodine treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.